Dynatronics (DYNT) Q2 2025 earnings summary

Executive summary

• Net sales for the quarter ended December 31, 2024, decreased 10.4% year-over-year to $7.3 million, primarily due to lower OEM volume and reduced demand for orthopedic soft bracing products.

• Gross profit margin improved slightly to 22.5% for the quarter, driven by higher margins in physical therapy and rehabilitation products.

• Net loss attributable to common stockholders narrowed to $960,000 for the quarter, or $0.13 per share, compared to $1.2 million, or $0.27 per share, in the prior year quarter.

• Management implemented cost-control initiatives, reducing SG&A expenses by 15.1% for the quarter and expects further benefits in fiscal 2025.

• Substantial doubt about the company's ability to continue as a going concern was raised, but management forecasts sufficient liquidity for the next twelve months due to ongoing cost reductions and operational optimizations.

Financial highlights

• Net sales for the six months ended December 31, 2024, declined 14.9% year-over-year to $14.9 million.

• Gross profit for the six months was $3.6 million (24.3% of sales), down from $4.1 million (23.6%) in the prior year period.

• Net loss for the six months was $1.1 million, an improvement from $1.3 million in the prior year period.

• Cash and cash equivalents increased to $791,000 as of December 31, 2024, from $484,000 at June 30, 2024.

• Working capital decreased to $1.89 million from $2.85 million at June 30, 2024.

Outlook and guidance

• Management expects continued benefits from cost-control initiatives in fiscal 2025 and 2026, including $1 million in annualized expense reductions and further facility optimizations.

• The company projects sufficient liquidity to meet obligations for the next twelve months, but notes ongoing risks from economic uncertainty and supply chain challenges.